Key Takeaways
- AstraZeneca shares plummeted up to 9% following Wainua’s disappointing late-stage trial results for heart disease
- The experimental drug failed to demonstrate a reduction in cardiovascular deaths and heart complications in ATTR-CM patients during the 140-week study period
- More than half of study participants (57%) were receiving stabilizer medications at enrollment, potentially obscuring Wainua’s therapeutic impact
- Industry experts pointed to fundamental issues with study architecture rather than drug efficacy problems, though concerns about company credibility emerged
- Ionis Pharmaceuticals shares declined 13.8% before market open; competitor Alnylam jumped 17%
Shares of AstraZeneca experienced a dramatic decline of up to 9.1% during London market hours Thursday, marking the pharmaceutical giant’s steepest single-session loss since March 2020, following disappointing results from its experimental cardiac medication Wainua in advanced clinical testing.
AZN stock traded on the New York Stock Exchange dropped 8.4% during premarket activity, erasing approximately £23.3 billion ($31.21 billion) from the company’s total market capitalization at its lowest point.
The pharmaceutical candidate underwent evaluation in 1,432 individuals diagnosed with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM), an uncommon disorder characterized by abnormally folded protein accumulation in cardiac tissue, which impairs the heart’s blood-pumping capacity. Between 300,000 and 500,000 individuals worldwide are estimated to be affected by this condition.
Wainua did not demonstrate a statistically meaningful decrease in heart-related mortality and repeated cardiovascular complications throughout the 140-week observation period when measured against placebo treatment, AstraZeneca announced in Thursday morning’s official statement.
Study Architecture Faces Scrutiny
The outcome surprised industry observers. Most had anticipated the trial would succeed, particularly given encouraging data from Amvuttra, a competing therapy developed by Alnylam Pharmaceuticals.
The root issue appears connected to the study’s fundamental structure. More than half (57%) of enrolled patients were already receiving stabilizer medications when the research began, with an additional 24% initiating stabilizer treatment during the trial period. Because stabilizers operate through a distinct mechanism compared to Wainua — classified as a gene silencing agent — combining both therapeutic approaches complicated the assessment of any incremental clinical advantage.
Among participants who were not receiving stabilizer therapy at baseline, Wainua demonstrated a “nominally significant” therapeutic effect. However, this subset analysis proved insufficient to satisfy the study’s primary efficacy measure.
Analysts at Jefferies observed that AstraZeneca “is meant to be able to have exceptionally good trial design ability,” noting that this design-related failure would negatively impact leadership’s reputation. The investment firm has reduced its risk-adjusted revenue projections for the drug by $2.5 billion.
BofA analyst Sachin Jain characterized the outcome as “a surprise,” highlighting that market participants had not factored in a miss scenario considering the positive competitor information already available.
Future Trajectory for Wainua
Barclays analysts indicated they do not anticipate AstraZeneca will finance another monotherapy study for Wainua, as such an approach would be improbable to secure regulatory approval within this decade and would fall considerably behind Alnylam’s already firmly established therapeutic option.
Citi’s research team added that pursuing supplementary regulatory approvals for Wainua in ATTR-CM appears improbable at this stage, particularly with Alnylam’s Amvuttra already authorized for treating this indication.
Wainua’s current regulatory authorization remains unchanged. The medication has received approval across more than 20 nations for polyneuropathy treatment — a nerve-damaging disorder — and contributed $212 million in product sales for AstraZeneca during 2025.
Jefferies emphasized that this setback does not jeopardize AstraZeneca’s ambitious $80 billion annual revenue objective for 2030, which relies on launching up to 20 novel pharmaceutical products. The analysts suggested the stock might remain under pressure until data from the AVANZAR oncology trial becomes available.
Ionis Pharmaceuticals, the U.S.-listed development partner, declined 13.8% in premarket sessions. Alnylam climbed 17% while BridgeBio advanced between 11% and 16%.
AstraZeneca stated the findings “support greater scientific understanding of treatment approaches” for individuals living with ATTR-CM.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
